M&A & Accretion/Dillution
M&A Deal Logic and Accretion/Dilution
Mergers and acquisitions (M&A) are transactions in which two companies combine, either by merging into a single entity or by one company buying another. A merger creates value only if the combined company is worth more than the two apart. Accretion and dilution measure the effect on earnings per share, not whether the deal was wise. The logic runs on synergies, the price paid, and how the deal is funded with cash, debt or stock. Learn to read a deal the way a banker does, and you can tell a genuinely value-creating acquisition from an expensive mistake dressed up as growth.
Start Learning →
M&A Deal Logic and Accretion/Dilution
LEARNING OBJECTIVES
IMPORTANCE
This is where the whole curriculum comes together. An acquisition is valued with a DCF and multiples, paid for with cash or stock from the balance sheet, and judged on whether the combined business is worth more than the price.
It is also where the most value is destroyed in finance. Most acquisitions fail to reward the acquirer, because the buyer overpays and the promised synergies disappoint. The discipline of this pillar is the guard against that.
The central insight: A deal that lifts is not automatically a good deal. Value is created only when what you get is worth more than what you pay.
INTELLECTUAL ORIGINS
The case for any merger is : the idea that two companies combined are worth more than the sum of their parts, through cost savings and new revenue. The arithmetic of two-plus-two-equals-five is the entire justification.
The empirical record is humbling. Decades of studies show most acquisitions create little or no value for the buyer's shareholders, because the seller captures the synergy through the premium. That is the winner's curse, and it is why a disciplined buyer fixes a before it bids.
CORE FRAMEWORK
. A strategic buyer is an operating company buying a competitor or complement for synergies and long-term ownership; it can pay more, because the asset is worth more in its hands. A financial buyer is a private-equity firm buying for a return; it is price-disciplined and uses leverage. The strategic buyer usually pays the higher price.
The . To take control, an acquirer pays above the target's market price, typically a 20 to 40 percent premium. Control is worth paying for, because the owner can direct the cash, the strategy, and the synergies.
. Cash, stock, or a mix.
, ranked by credibility. Cost synergies, removing duplicated functions and buying at greater scale, are concrete and usually delivered. Revenue synergies, cross-selling and new markets, are real but soft, and should be valued conservatively or not at all.
The . Does the deal raise or lower the acquirer's earnings per share? Combine the two companies' earnings, combine the share counts, and see if EPS rises () or falls (). The quick rule for a stock deal: accretive if the acquirer's P/E is higher than the multiple it pays for the target; dilutive if lower. A high-P/E acquirer is paying with expensive shares, so it can buy a cheaper target's earnings and lift its own EPS.
Two separate questions. Accretion is not value, and dilution is not failure. They sit on different axes. Accretion/dilution is only the EPS arithmetic. Whether value is created is a separate test entirely: did the price stay below the maximum, the target's standalone value + the present value of real synergies? A deal can lift EPS and still destroy value by overpaying, or dilute EPS and still create value by buying a great asset cheap. Overpaying is what destroys value and seeds a future goodwill write-down, not the EPS effect.
THE THEORY IN DEPTH
Mergers and acquisitions are where strategy meets arithmetic. Behind every deal sits a simple test that cuts through the ambition and the storytelling: does the acquisition actually make each remaining share more valuable, or less?
Why companies acquire other companies
The honest reasons for a deal come down to creating value that the two businesses could not create apart:
Not every stated reason is a real one. Deals are also driven by ambition and empire-building, which is exactly why a hard financial test matters.
How a deal is actually paid for
An acquirer can pay in cash, in its own shares, or in a mix of both.
The choice matters enormously, because it changes who bears the risk and how the ownership is divided afterwards.
Paying in cash often uses debt or reserves. Paying in shares issues new stock, dividing the combined company among more owners. How a deal is financed can matter as much as the price paid.
What accretion and dilution mean
The clearest test of a deal's immediate effect is what it does to earnings per share:
If a company issues many new shares to buy only modest extra earnings, each existing share ends up owning less, and the deal is dilutive. If the earnings acquired outweigh the new shares issued, it is accretive.
Why accretion is not the same as value
A deal can raise earnings per share and still destroy value, and it can lower earnings per share and still create it.
Accretion measures the short-term arithmetic, not whether the price paid was sensible.
The deeper question is always the one an investor asks of any purchase: was the business bought for less than it is worth? Accretion and dilution are the first check, never the final verdict.
COMPARISON
| Cash deal | Stock deal | |
|---|---|---|
| How funded | Cash on hand or new debt | New shares issued to the seller |
| Share count | Unchanged | Rises (dilution) |
| Who bears the risk | The acquirer alone | Shared with the seller, now a shareholder |
| EPS rule of thumb | Accretive if target earnings yield > after-tax cost of funding | Accretive if acquirer P/E > target P/E |
| Best when | The acquirer is confident and funding is cheap | The acquirer's shares are richly valued, or cash is scarce |
REAL COMPANY APPLICATION: AMD AND XILINX
These figures illustrate the logic of a real deal; they are not a valuation. The full company model is in Equity Research, under the AMD analysis.
In February 2022, AMD acquired Xilinx for about $49B in an all-stock deal, the most expensive semiconductor acquisition ever at the time.
LIMITATIONS
COMPETING VIEWS
The disciplined reading values the target standalone, adds only credible synergies, fixes a maximum price, and treats accretion as a side effect rather than the objective.
IN SUMMARY
A merger is worth doing only when the combined company is worth more than the two apart, and only when the buyer pays less than the target's standalone value plus the present value of real synergies. Strategic buyers pay control premiums of 20 to 40 percent; deals are funded in cash or stock, each with its own effect; cost synergies are credible and revenue synergies are not. Accretion and dilution measure the EPS effect of a deal, not its wisdom. AMD's $49B all-stock purchase of Xilinx shows it all: sound strategy, a rich price, a mountain of goodwill, and a return that has to be earned over years.
RELATED TOPICS
Pillar 3, Balance Sheet Deep Dive. Where the goodwill from a deal sits.
Pillar 6, Enterprise Value vs Equity Value. How a target is priced.
Pillar 8, DCF Modeling. How synergies and the target are valued.
Pillar 9, LBO Modeling Basics. The financial buyer's version of an acquisition.
FURTHER READING
REFLECTION QUESTIONS
The additional value that two companies are worth together but not apart, through cost savings or new revenue. It is the entire justification for a merger, the arithmetic of two-plus-two-equals-five, and the part most often overestimated.
When AMD bought Xilinx, the case rested on combining Xilinx's programmable chips with AMD's CPUs and GPUs to reach data-centre and embedded markets, synergy worth more than either firm alone.
Synergy is what a buyer pays the premium for, so its credibility, cost synergies more than revenue, decides whether a deal creates value.
The highest price a buyer can rationally pay: the target's value on its own plus the present value of the synergies the deal creates. Pay less and the buyer keeps value; pay more and it hands value to the seller.
AMD's willingness to pay a record price for Xilinx was justified only if the standalone value plus genuine synergies exceeded the $49B paid, a judgement still being tested by Xilinx's returns.
The maximum price is the discipline that separates a good deal from a bad one, independent of whether the deal happens to be accretive to earnings.
Two kinds of acquirer. A strategic buyer is an operating company buying for synergies and long-term ownership, and can pay more because the asset is worth more in its hands. A financial buyer is a private-equity firm buying for a return, price-disciplined and using leverage.
AMD buying Xilinx is a strategic acquisition, paying for long-term technological fit. A private-equity buyout of Cheesecake would be financial, focused on leverage and exit returns.
The strategic buyer usually pays the higher price, because it values control and synergies that a financial buyer does not.
The amount an acquirer pays above a target's market price to gain control of it, typically 20 to 40 percent. Control is worth paying for, because the owner can direct the cash, the strategy, and the synergies.
AMD paid well above Xilinx's standalone value to take control, a premium justified by the strategic synergies it expected to capture.
The premium is the price of control, and it is also the reason most of a deal's synergy often ends up with the seller rather than the buyer.
The two ways to pay for an acquisition. A cash deal uses cash or new debt, issues no shares, and leaves the acquirer bearing all the risk. A stock deal issues new shares to the seller, who becomes a shareholder and shares the risk.
AMD bought Xilinx in an all-stock deal worth about $49B, issuing new shares rather than paying cash, which suited a buyer whose own stock was richly valued.
Cash suits a confident buyer with cheap funding or an undervalued stock; stock suits a buyer whose shares are richly valued or whose cash is scarce, and each choice changes who bears the risk.
Whether a deal raises (accretive) or lowers (dilutive) the acquirer's earnings per share, found by combining the two companies' earnings and share counts. For a stock deal the quick rule is: accretive if the acquirer's P/E is higher than the multiple it pays for the target.
AMD paid a rich multiple for Xilinx in stock, so the deal was slow to add to earnings, and its return on the capital is still recovering years later.
Accretion and dilution are an EPS effect only, on a separate axis from value: a deal can lift EPS and still destroy value by overpaying, or dilute EPS and still create it by buying a great asset cheaply.
The premium an acquirer pays above the fair value of a target's net assets, recorded as an asset on the balance sheet. It is non-cash and cannot be sold, and it faces a write-down if the acquisition disappoints.
AMD's purchase of Xilinx left about $25B of goodwill on its balance sheet, close to 30 percent of total assets. If Xilinx's returns fall short, that goodwill is a candidate for impairment.
A goodwill write-down lowers the balance sheet and runs through the income statement as a charge, the public admission that a deal destroyed value, though it costs no cash.
Synergies are the honest justification for many deals. They are also easy to overstate, which is why a hard financial test matters.
Earnings per share is what accretion and dilution are measured against. Issuing many shares to buy modest profit lowers it, and the deal is dilutive.
A deal is accretive when the earnings it adds outweigh the new shares issued to pay for it. Accretion is a first check, not proof of value.
A deal is dilutive when a company issues many shares to buy only modest extra earnings. Lower earnings per share can still create value, and the reverse.